Late effects of treatment for Hodgkin lymphoma.
Late effects of treatment for Hodgkin lymphoma.
复制标题
霍奇金淋巴瘤治疗的后期效果。
DOI：
10.6004/jnccn.2006.0024
复制
发表时间：
2006
期刊：
影响因子：
--
通讯作者：
L. Constine
中科院分区：
文献类型：
--
作者：
D. Friedman;L. Constine
随着多模式治疗的进步，霍奇金淋巴瘤（HL）的生存率现已超过80%，导致大量存活者面临治疗不良长期后遗症的风险。这种风险因可能的内源性倾向而变得复杂，从而导致发生晚期效应，这与患者对HL的潜在易感性有关。最后，HL对宿主的影响可损害器官功能。本文综述了HL幸存者可能的显性晚期效应以及监测和筛查策略。随着HL治疗的变化和发展，晚期效应谱也在变化和发展。HL的死亡率降低，而治疗的延迟效应增加。随着HL治愈的成功，治疗的改进以降低毒性。因此，使用风险适应策略的治疗方案的修改减少了与不良长期后遗症相关的烷化剂、蒽环类药物和放疗的使用。临床上最明显的后遗症是那些涉及内分泌和心血管系统，最病态的是血液和固体第二恶性肿瘤。随着对治疗延迟效应认识的增加，可以制定一级和二级预防策略。
With advances in multimodality therapy, survival from Hodgkin lymphoma (HL) now exceeds 80%, resulting in a large cohort of survivors who are at risk for adverse long-term sequelae of therapy. This risk is complicated by possible endogenous predispositions to developing late effects, which relate to the patient's underlying susceptibility to HL. Finally, the impact of HL on the host can compromise organ function. This article reviews the possible dominant late effects for survivors of HL and strategies for monitoring and screening. As therapy for HL has changed and evolved, so has the spectrum of late effects. Mortality from HL has decreased, whereas delayed effects of therapy have increased. Refinements in therapy to decrease toxicity have occurred in response to the success in curing HL. Thus, modifications in therapeutic protocols using a risk-adapted strategy have reduced the use of alkylating agents, anthracyclines, and radiotherapy, which are associated with adverse long-term sequelae. The most clinically evident sequelae are those involving the endocrine and cardiovascular systems, and the most morbid are hematologic and solid second malignancies. Primary and secondary prevention strategies can be developed as knowledge of delayed effects of therapy increases.
登录
查看更多内容
DOI：
10.1016/s0360-3016(96)00295-7
发表时间：
1996-11-01
影响因子：
7
作者：
King, V;Constine, LS;Rubin, P
通讯作者：
Rubin, P
霍奇金病幸存者的甲状腺异常：来自儿童癌症幸存者研究的数据。
DOI：
10.1210/jcem.85.9.6808
发表时间：
2000
期刊：
The Journal of clinical endocrinology and metabolism
影响因子：
--
作者：
Sklar,C;Whitton,J;Mertens,A;Stovall,M;Green,D;Marina,N;Greffe,B;Wolden,S;Robison,L
通讯作者：
Robison,L
儿科霍奇金病：联合治疗后的肺、心脏和甲状腺功能。
DOI：
10.1016/0360-3016(89)90485-9
发表时间：
1989
期刊：
International journal of radiation oncology, biology, physics
影响因子：
--
作者：
Mefferd,JM;Donaldson,SS;Link,MP
通讯作者：
Link,MP
影响因子：
120.7
作者：
Travis, LB;Hill, DA;Gilbert, E
通讯作者：
Gilbert, E
影响因子：
45.3
作者：
HANCOCK, SL;DONALDSON, SS;HOPPE, RT
通讯作者：
HOPPE, RT